Wasser Departs Reagan-Udall Foundation for the FDA
June Wasser Departs Reagan-Udall Foundation for the FDA
Amar Bhat, PhD, named Interim Executive Director
Washington, DC, April 16, 2019 -- Ellen V. Sigal, PhD, Board Chair of the Reagan-Udall Foundation for the FDA, today announced that June Wasser is stepping down as the Foundation’s Executive Director. In accepting the resignation, effective in early May, Dr. Sigal lauded Ms. Wasser’s leadership during the past three years, noting that she has helped build the organization from a small start-up to a position of strength by expanding meaningful programs and initiatives.
“Under June’s guidance, the organization achieved several firsts,” notes Dr. Sigal, “including publication of our first IMEDS studies, launch of the Expanded Access Navigator, and presentation of our inaugural Innovations in Regulatory Science Awards.”
The Foundation’s Board of Directors appointed Amar Bhat, PhD, as the Interim Executive Director. Dr. Bhat joined the organization a year ago managing a portfolio focused on strategic planning and program development. In the past two decades, he has held a variety of executive positions in industry, government, science, and health policy. The Foundation plans to launch a national search to fill the Executive Director position this spring.
About the Reagan-Udall Foundation for the FDA
Home to the Innovation in Medical Evidence Development and Surveillance (IMEDS) program and the Expanded Access Navigator, the Reagan-Udall Foundation for the FDA is a congressionally chartered 501(c)3 that advances regulatory science and supports the mission of the FDA. The Foundation creates public-private partnerships that facilitate innovation, foster the use of real-world evidence, and identify modern tools and policies to keep pace with today’s rapidly evolving science. To learn more, please visit reaganudall.org.
Lea Ann Browning-McNee